Zetagen Receives Approval in Australia to Begin Pilot Study of ZetaFuse® Bone Graft to Treat Cervical Degenerative Disc Disease
November 6, 2023, (Syracuse, New York) - Zetagen Therapeutics, a private, clinical-stage, biopharmaceutical company focused on driving breakthrough innovation in the treatment of metastatic cancers to bone and soft tissue organs as well as osteologic interventions, today announced its approval from the Human Research Ethics Committee (HREC) of Australia to begin a pilot study using its novel therapy ZetaFuse® bone graft for the treatment of cervical degenerative disc disease. The pilot study is a randomized, open-label, two-level cervical program which will examine the safety and efficacy of ZetaFuse® bone graft in patients undergoing anterior cervical discectomy and fusion (ADCF) surgery.